Publicacións nas que colabora con José Ignacio García Doval (16)

2019

  1. How real are ‘real-life studies’ in psoriasis, and the uncertain meaning of drug persistence

    British Journal of Dermatology

2017

  1. Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 3-5

  2. Drug Survival Analysis Is Not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 1, pp. 3-5

  3. Factors associated with receiving biologics or classic systemic therapy for moderate-to-severe psoriasis: Evidence from the psonet registries

    Acta Dermato-Venereologica

  4. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

    Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321

  5. Response to the Comment by Van den Reek et al. on Drug Survival Analysis is not a Good Method for Assessing the Safety or Effectiveness of Systemic Therapies in Psoriasis

    Actas Dermo-Sifiliograficas

2016

  1. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

    Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950

2015

  1. Prioritization of therapy uncertainties in congenital ichthyosis: Results from a Priority Setting Partnership

    British Journal of Dermatology, Vol. 173, Núm. 5, pp. 1280-1283

2014

  1. Current dystrophic epidermolysis bullosa research does not match research needs perceived by patients and clinicians

    Journal of the American Academy of Dermatology, Vol. 71, Núm. 5, pp. 1008-1011

  2. Description of dermatological hospitalization in Spain (2005-2010). Population-based data from the minimum data set

    Piel, Vol. 29, Núm. 9, pp. 546-551

  3. The Use of systematic reviews in clinical trials and narrative reviews in dermatology: Is the best evidence being used?

    Actas Dermo-Sifiliograficas, Vol. 105, Núm. 3, pp. 295-299

2013

  1. Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: Where should research direct to? an example of priority setting partnership in very rare disorders

    Orphanet Journal of Rare Diseases, Vol. 8, Núm. 1

  2. Schwannoma plexiforme: Presentación de un caso y diagnóstico diferencial histopatológico

    Medicina Cutanea Ibero-Latino-Americana, Vol. 41, Núm. 3, pp. 122-125

  3. Updated systematic review of randomized controlled trials of treatments for inherited forms of epidermolysis bullosa

    Clinical and Experimental Dermatology

  4. Usefulness of cochrane skin group reviews for clinical practice

    Actas Dermo-Sifiliograficas, Vol. 104, Núm. 8, pp. 679-684

2012

  1. Anestesia tumescente en cirugía dermatológica

    Actas Dermo-Sifiliograficas, Vol. 103, Núm. 4, pp. 285-287